dacarbazine has been researched along with ly2109761 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Han, N; Hauser, K; Herion, TW; Huber, PE; Lahn, M; Peschke, P; Timke, C; Weber, KJ; Wirkner, U; Zhang, M | 1 |
1 other study(ies) available for dacarbazine and ly2109761
Article | Year |
---|---|
Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cells, Cultured; Combined Modality Therapy; Dacarbazine; Gene Expression Regulation, Neoplastic; Glioblastoma; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Platelet Endothelial Cell Adhesion Molecule-1; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Radiotherapy; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |